WallStSmart

Inogen Inc (INGN)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 7192% more annual revenue ($25.84B vs $354.30M). SYK leads profitability with a 14.4% profit margin vs -6.9%. SYK appears more attractively valued with a PEG of 1.15. SYK earns a higher WallStSmart Score of 67/100 (B-).

INGN

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 2.0Value: 5.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.71

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INGNUndervalued (+88.9%)

Margin of Safety

+88.9%

Fair Value

$55.09

Current Price

$5.31

$49.78 discount

UndervaluedFair: $55.09Overvalued
SYKSignificantly Overvalued (-19.9%)

Margin of Safety

-19.9%

Fair Value

$229.73

Current Price

$275.56

$45.83 premium

UndervaluedFair: $229.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INGN3 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
87.3%10/10

Earnings expanding 87.3% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$105.70B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

INGN4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.0%4/10

3.0% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Market CapQuality
$143.04M3/10

Smaller company, higher risk/reward

PEG RatioValuation
3.482/10

Expensive relative to growth rate

SYK2 concerns · Avg: 3.5/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INGN

The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : INGN

The primary concerns for INGN are Revenue Growth, Altman Z-Score, Market Cap.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

INGN profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

INGN carries more volatility with a beta of 1.60 — expect wider price swings.

SYK is growing revenue faster at 9.4% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (67/100 vs 49/100). INGN offers better value entry with a 88.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Inogen Inc

HEALTHCARE · MEDICAL DEVICES · USA

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?